Gt Biopharma, INC

GT Biopharma has amended its bylaws to lower the shareholder quorum requirement from a majority to one-third of outstanding shares.

GT Biopharma has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement.

GT Biopharma has entered into a $3.8 million clinical trial agreement with the University of Minnesota to advance its GTB-5550 TriKE candidate for solid tumors.

GT Biopharma, Inc. announced a restatement of its Q2 and Q3 2025 financial statements due to an accounting error related to Greenshoe Rights.

GT Biopharma, Inc. received a notice from Nasdaq regarding non-compliance with the $1 minimum bid price requirement, initiating a 180-day compliance period.

GT Biopharma announced its third quarter 2025 financial results, highlighting progress in its GTB-3650 clinical trial and anticipated IND submission for GTB-5550.

GT Biopharma reports a wider net loss for Q1 2026 compared to the prior year, driven by increased selling, general, and administrative expenses, while research and development costs decreased.

GT Biopharma, Inc. has filed an amended quarterly report for Q2 2025, restating financials due to material errors in classifying Greenshoe Rights as a liability, significantly increasing net loss and accumulated deficit.

GT Biopharma, Inc. has filed an amended quarterly report for Q3 2025 to correct material errors related to Greenshoe Rights liability classification, while reporting a wider net loss for the nine months ended September 30, 2025.

GT Biopharma reported a significantly reduced net loss and a return to positive stockholders' equity for the nine months ended September 30, 2025, while advancing its TriKE immuno-oncology pipeline.

GT Biopharma reports a narrowed net loss for Q2 2025, highlights progress in clinical trials, and raises concerns over liquidity challenges.

GT Biopharma reports a net loss of $776,000 for Q1 2025, highlighting advancements in clinical trials and cost-cutting measures.

GT Biopharma, a clinical-stage biopharmaceutical company, reported a significant net loss and substantial doubt about its ability to continue as a going concern, despite advancing its TriKE product pipeline.

GT Biopharma files an amendment to its 2024 Form 10-K to include the company's Compensation Recovery Policy as an exhibit.

GT Biopharma's 2024 10-K filing reveals ongoing clinical development of its TriKE platform, challenges in maintaining Nasdaq listing compliance, and a net loss of $13.2 million.

GT Biopharma's 2023 annual report highlights a year of clinical development progress and financial adjustments, including a reverse stock split and a focus on next-generation TriKE therapies.

GT Biopharma Director David C. Mun-Gavin acquired 31,250 options to purchase common stock at an exercise price of $1.33.

GT Biopharma's CEO and Director, Michael Martin Breen, acquired 300,000 options to purchase common stock at an exercise price of $1.33 per share.

GT Biopharma's Chief Financial Officer, Alan Urban, was granted 100,000 stock options with an exercise price of $1.33, vesting quarterly over two years.

GT Biopharma Director Charles J. Casamento acquired 62,500 stock options, fully vested and exercisable, with an exercise price of $1.33.

GT Biopharma Director Hilary Kramer reported the acquisition of 31,250 stock options with an exercise price of $1.33.

Alan Urban, CFO of GT Biopharma, acquired options to purchase 23,335 shares of common stock on October 17, 2024.

GT Biopharma, Inc. has filed a Definitive Proxy Statement (DEFA14A) with the U.S. Securities and Exchange Commission.

GT Biopharma, Inc. is calling its stockholders to an Annual Meeting on July 24, 2025, to vote on critical proposals including the election of directors, ratification of auditors, an advisory vote on executive compensation, and, most notably, the approval of substantial share issuances and an expansion of its equity incentive plan.

GT Biopharma reminds stockholders holding 100 or more shares to vote before the upcoming Annual Meeting on June 25, 2024.

GT Biopharma has filed a definitive proxy statement with the SEC.

GT Biopharma will hold its annual stockholders meeting virtually on June 25, 2024, to vote on the election of directors, ratification of independent accountants, and executive compensation.

GT Biopharma, Inc. has filed a registration statement for the resale of up to 9,723,057 shares of common stock by existing stockholders.

GT Biopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of 22.6 million shares of common stock by existing selling stockholders, while facing Nasdaq delisting risk and going concern doubts.

GT Biopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 14.59 million common shares by selling stockholders, stemming from recent private placements and advisory agreements.

GT Biopharma, a clinical-stage biopharmaceutical company, has filed an amended registration statement to allow selling stockholders to resell up to 54.4 million shares, including those from a recent private placement and a new $20 million committed equity facility, while disclosing a 'going concern' doubt and recent Nasdaq compliance regain.

GT Biopharma, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for the resale of up to 120.5 million shares by selling stockholders, while simultaneously addressing a Nasdaq listing compliance issue and disclosing substantial doubt about its ability to continue as a going concern.

GT Biopharma is launching a public offering of common stock and warrants to raise capital for the development of its TriKE and Dual Targeting TriKE immuno-oncology products.

Bristol Investment Fund, Ltd. and Bristol Capital, LLC have filed an amendment to their Schedule 13G, disclosing their continued passive beneficial ownership in GT Biopharma, Inc.'s common stock.

Five Narrow Lane LP has reported a passive beneficial ownership of 9.99% in GT Biopharma, Inc., holding 253,388 shares of common stock.